Cited by 50MicroRNA in disease regulationCancer-related molecular mechanisms researchGlioma Diagnosis and Treatment

Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L

Open access
ZHAO, WEI-HUA, WU, SHENG-QI, ZHANG, YANG-DE·2013·International Journal of Molecular Medicine

Abstract

microRNA-124 (miR-124) plays an important role in regulating growth, invasiveness, stem-like traits, differentiation and apoptosis of glioblastoma cells. PPP1R3L, an inhibitory member of the apoptosis-stimulating protein of p53 family (IASPP), is also able to affect growth, cell cycle progression, metastasis and apoptosis of various types of cancer. To investigate the regulation of PPP1R13L expression by miR-124 and their effects on proliferation, cell cycle transition and invasion in glioblastoma cells, U251 and U373 glioblastoma cells were transfected with miR-124 mimics, its negative control (NC) or an inhibitor. We found that miR-124 was downregulated in glioblastoma tissues, and inversely regulated PPP1R13L expression in U251 and U373 glioblastoma cells. PPP1R13L was found to be a direct target of miR-124 in glioblastoma cells. Overexpression of miR-124 inhibited proliferation, G1/S transition and invasiveness in glioblastoma cells. miR-124 downregulation-mediated malignant progression of glioblastoma was partly attributed to increased PPP1R13L expression. Consequently, our findings provide a molecular basis for the role of miR-124/PPP1R13L in the progression of human glioblastoma and suggest a novel target for the treatment of glioblastoma.

Integrity signals

Registry

Crossref · 10.3892/ijmm.2013.1365

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mir-124 targets PPP1R13L, a p53 pathway inhibitor, and reduces glioblastoma cell proliferation, cell cycle progression, and invasion.

    “Mir-124 targets PPP1R13L, a p53 pathway inhibitor, and reduces GBM cell proliferation, cell cycle progression, and invasion.”

    From The p53 Pathway in Glioblastoma (2018) · cites this paper as [53]

Cited by

Sorted by citations

Authors
ZHAO, W.-H., WU, S.-Q., & ZHANG, Y.-D.
Venue
International Journal of Molecular Medicine
Published
2013-04-29
Volume
32
Issue
1
Pages
101-107
ISSN
  • 1107-3756 (ISSN-L)
  • 1791-244X
OpenAlex
W2151845348
Cited by
50
References
0
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 8 · 2016: 5 · 2015: 9 · 2014: 7 · 2013: 3
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
Keywords
miR-124, PPP1R13L, glioblastoma, tumor cell proliferation, tumor invasion, G1/S transition, microRNA target regulation, U251 cells, U373 cells, glioma progression
MeSH terms
Cell Cycle, Glioblastoma, Humans, Neoplasm Invasiveness, Repressor Proteins, Gene Expression Regulation, Neoplastic, MicroRNAs, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review